Johnson & Johnson is recommended by billionaires due to strong financials and recent acquisitions

From Yahoo Finance: 2025-04-13 17:41:00

Johnson & Johnson (NYSE: JNJ) is among the top medical stocks to buy, according to billionaires. Healthcare stocks are considered a safe haven amid trade uncertainties. However, the sector faces challenges like generic patent cliffs and price concessions, affecting investor confidence. Managed care and US-centric medical device stocks are relatively safer investments, according to experts.

Johnson & Johnson (NYSE: JNJ) is a healthcare giant with a strong financial standing, reporting $88.8 billion in sales for 2024, showing 4.3% year-over-year growth. The company recently acquired IntraCellular for $14.6 billion to access Caplyta, a drug for bipolar disorder and schizophrenia. Analysts have a positive outlook on JNJ, with price targets set at $172 and $164 by Goldman Sachs and Morgan Stanley, respectively.

While JNJ ranks 5th among billionaire-favored medical stocks, some believe AI stocks offer higher return potential. An AI stock has shown significant gains in 2025 compared to popular AI stocks. For investors seeking promising AI stocks trading at a low multiple of earnings, exploring alternatives to JNJ may be beneficial. JNJ remains a solid investment, but other opportunities may offer quicker and greater returns.



Read more at Yahoo Finance: Why Johnson & Johnson (JNJ) is the Best Medical Stock to Buy According to Billionaires